CRBP:NSD-Corbus Pharmaceuticals Holdings, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.95

Change

-0.05 (-4.61)%

Market Cap

USD 0.08B

Volume

1.90M

Average Target Price

USD 14.73 (+1,456.24%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-10-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals, Inc

-15.48 (-2.66%)

USD61.98B 22.47 17.37
VRTX Vertex Pharmaceuticals Incorpo..

-3.85 (-1.81%)

USD55.27B 26.75 20.98
SGEN Seagen Inc

-2.07 (-1.05%)

USD34.26B N/A N/A
MRNA Moderna, Inc

-4.93 (-6.98%)

USD27.89B N/A N/A
BGNE BeiGene, Ltd

-2.29 (-0.76%)

USD27.13B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-5.15 (-4.29%)

USD26.30B 32.43 29.34
RPRX Royalty Pharma plc

-1.75 (-4.62%)

USD22.99B 33.55 9.19
GMAB Genmab A/S

-1.30 (-3.72%)

USD22.92B 25.74 2.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
BNTX BioNTech SE

-6.41 (-7.64%)

USD19.78B -99,999.99 N/A

ETFs Containing CRBP

Symbol Name Weight Mer Price(Change) Market Cap
MJ ETFMG Alternative Harvest.. 0.00 % 0.75 %

-0.25 (-2.27%)

USD0.50B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -82.67% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.67% 2% F 1% F
Trailing 12 Months  
Capital Gain -81.55% 2% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.55% 2% F 2% F
Trailing 5 Years  
Capital Gain -41.94% 48% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.94% 48% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain 63.91% N/A N/A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.91% N/A N/A 94% A
Risk Return Profile  
Volatility (Standard Deviation) 144.08% N/A N/A 6% F
Risk Adjusted Return 44.36% N/A N/A 66% D
Market Capitalization 0.08B 25% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.70 84% B 59% F
Price / Cash Flow Ratio -1.77 25% F 64% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -240.39% 13% F 5% F
Return on Invested Capital -442.77% 2% F 1% F
Return on Assets -82.52% 5% F 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.51 42% F 28% F
Short Percent 53.00% 0% N/A 5% F
Beta 1.83 31% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector